A landmark study presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting is shedding new light on how compounds that are structurally identical to human milk oligosaccharides (HMOs) can significantly improve IBS symptoms within four weeks.
The study focuses on a unique formulation of two types of HMOs — 2’-FL (2’-fucosyllactose) and LNnT (lacto-N-neotetraose) found in IBS Restore, a medical food available without a prescription. Patients enrolled in the 12-week trial took the unique formulation once daily. Within four weeks 77% reported significant improvement in symptom severity. The symptom reductions include:
• 59% reduction in abdominal pain severity
• 59% decreased bloating
• 58% reduced days with abdominal pain
• 37% decreased number of abnormal stools
The HMOs used in the trial have been known to selectively nourish the “good bacteria,” enabling them to flourish and improve the body’s gut barrier. The findings in this new study supports the growing acceptance in the medical community of microbiota-directed therapies, such as the inclusion of prebiotic HMOs in IBS dietary planning.